Immunotherapy offers hope for newly diagnosed lung cancer patients

Researchers examine cell activity in early stage lung tumours and find they can be amenable to biologic therapy, as they already know advanced tumours to be.

Pap stain of pulmonary adenocarcinoma

Immunotherapy leads to significant responses in patients with advanced lung tumours but its benefit in early tumours remains unknown.

Researchers carried out immune profiling in order to map the microenvironment of early stage lung tumours. They took freshly resected stage I lung adenocarcinoma tumours from patients who were treatment naïve, along with samples of surrounding healthy lung tissue and blood samples, and simultaneously analysed them.

The researchers identified natural killer (NK) and myeloid cell responses unique to the tumour lesion and absent from the non-involved lung tissue or from the blood. In as early as stage I disease, the tumours had a strongly reduced CD8+ T effective/T regulatory cell ratio compared with the healthy lung tissue. NK cells were also strongly reduced in the tumours and phenotypically altered.

Publishing in Cell
(online, 4 May 2017), the researchers concluded that the finding provides a powerful tool for the rational design of early stage cancer immune therapies.


[1] Lavin Y, Kobayashi S, Leader A et al. Paired single-cell analyses identify a distinct innate immune landscape in early lung adenocarcinoma lesions. Cell 2017;169:750-765. doi: 10.1016/j.cell.2017.04.014

Last updated
The Pharmaceutical Journal, Immunotherapy offers hope for newly diagnosed lung cancer patients;Online:DOI:10.1211/PJ.2017.20202832

You may also be interested in